We also say thanks to the staff from the Radiochemistry/Cyclotron Primary at MSKCC. as an anticancer treatment. By depleting cancer cells of the semi-essential amino acidl-arginine (Arg), it has been shown in multicenter phase I/II trials to PF 477736 have beneficial effects in individuals suffering from irresectable hepatocellular carcinoma or metastasized malignant melanoma [14]. Due to the mutual characteristic of lacking the essential enzyme to get intrinsic Arg synthesis, argininosuccinate synthetase (ASS), these cancer entities encounter nutrient starvation and apoptotic cell death [5, 6]. More recent studies show that ADI could not only be an interesting therapeutic option in ASS-negative lung cancers but also explain that the present or missing expression of ASS in cancer cells can function as a predictive biomarker for the development of, e. g., pulmonary metastasis, and thus implies a potential target for pharmacologic intervention [7, 8]. Using quantitative molecular imaging modalities to assess and adhere to ADI treatment, however , offers so far failed. The use of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography (FDG PET), which has been well established as a biomarker in imaging treatment response in oncology, failed to show the ADI-associated clinical improvement due to IL5RA its cross-reactivity with the PI3K signaling axis [911]. Still, PF 477736 finding a noninvasive way to follow and evaluate ADI treatment would be desirable for its further translation into clinic, as the early identification of responders and non-responders is particularly crucial to get the patients’ outcome and management. Based on this premise and the fact that FDG PET did not reveal the effective therapeutic intervention with ADI, we choose the clinically established tracer 3-[18F]fluoro-3-deoxythymidine (FLT PET), which objects proliferation by representing DNA synthesis [12, 13]. Relating to initial findings [10], we used an analogous experimental set up PF 477736 and, in a proof-of-principle approach, aimed to evaluate FLT PET in treatment response of melanoma xenograft mice undergoing ADI therapy. == Material and Methods == == Components == The melanoma cell lines SK-MEL-10 and SK-MEL-28 were obtained from Memorial Sloan-Kettering Cancer Center and managed in glucose-containing RPMI and DMEM, respectively, supplemented with 10 % fetal calf serum, l-glutamine, and 100 g/ml penicillin-streptomycin at 37 C and five % CO2. ADI-EG 20 was provided by DesigneRx Pharmaceuticals Inc., Vacaville, CA, USA, a subsidiary of Polaris Group, San Diego, CA, USA. To get immunoblot analysis of protein expression levels, -ASS (BD Biosciences, Franklin Lakes, NJ, USA), –actin (AC-15, GeneTex, Irvine, CA, USA), -PTEN (Cell Signaling Technology, Danvers, MA, USA), -p53 (Cell Signaling Technology), -mouse, and -rabbit IgG-HRP secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used in accordance to manufacturer’s instructions. Statistical analysis of all data (studentttest) was performed with Prism 5. 0 (GraphPad, La Jolla, CA, USA) and Microsoft Excel 2008 to get Mac Edition 12. 0. Apvalue <0. 05 was viewed as significant. Error bars symbolize standard error of the mean (SEM). == ADI Dosing Studies in Xenograft Versions == Almost all animal studies were conducted in accordance with the institutional guidelines established at the Memorial Sloan-Kettering Cancer Center (MSKCC). Subcutaneous SK-MEL-28 xenografts were established by injecting 4106cells in Matrigel (BD, Franklin Lakes, NJ, USA) in the shoulder region of 68-week-old female NOD-SCID mice (NOD. CB17-Prkdcscid/J, Jackson Laboratory, Club Harbor, ME, USA). The mice PF 477736 were randomized into control (PBS, n=3 each) and ADI groups (n=5 each) to get PET imaging and further weekly histopathological work-up. Seven days post inoculation (average tumor volume=500 mm3), the mice received weekly intramuscular injections of ADI (160 PF 477736 U/m2, equal to approx. 17. 8 mg/m2) or PBS. Body weight and tumor volume (caliper measurements: calculation: 2/3 ((diameter 1+diameter 2)/2)3) were measured once a week for 4 weeks. == FLT PET Imaging of Xenograft Models == PET imaging was performed once a week prior to each treatment. All mice were injected with about 0. three or more mCi (11. 1 MBq) of18F-FLT via a lateral tail vein. After 1 h of tracer uptake, the animals were anesthetized with 12 % isoflurane (Baxter Healthcare, Deerfield,.